To evaluate the efficacy of reirradiation and systemic chemotherapy as salvage treatment in patients with recurrent malignant glioma. Between May 2006 and December 2011, 54 patients with recurrent malignant glioma received hypofractionated stereotactic radiotherapy (HSRT) plus systemic therapy at University of Rome Sapienza, Sant' Andrea Hospital. All patients had Karnofsky performance score ≥60 and were previously treated with standard conformal RT (60 Gy) with concomitant and adjuvant temozolomide (TMZ) up to 12 cycles. Thirty-eight patients had a GBM and 16 patients had a grade 3 glioma. The median time interval between primary RT and reirradiation was 15.5 months. At the time of recurrence all patients received HSRT (30 Gy in 6-Gy fractions) plus concomitant TMZ (75 mg/m2/day) followed by continuous TMZ at 50 mg/m2 everyday up to 1 year or until progression. Median overall survival after HSRT was 12.4 months, and the 12- and 24-month survival rates were 53 and 16 %, respectively. The median progression-free survival (PFS) was 6 months, and the 12- and 24-month PFS rates were 24 and 10 %, respectively. KPS >70 (P = 0.04) and grade 3 glioma were independent favourable prognostic factors for survival. In general chemoradiation regimen was well tolerated with relatively low treatment-related toxicity. HSRT plus concomitant TMZ followed by continuous dose-intense TMZ is a feasible treatment option associated with survival benefits and low risk of complications in selected patients with recurrent malignant glioma. The potential advantages of combined chemoradiation schedules in patients with recurrent malignant gliomas need to be explored in future studies. © 2012 Springer Science+Business Media New York.

Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas / Giuseppe, Minniti; Scaringi, Claudia; DE SANCTIS, Vitaliana; Gaetano, Lanzetta; Falco, Teresa; D., Di Stefano; Esposito, Vincenzo; MAURIZI ENRICI, Riccardo. - In: JOURNAL OF NEURO-ONCOLOGY. - ISSN 0167-594X. - STAMPA. - 111:2(2013), pp. 187-194. [10.1007/s11060-012-0999-9]

Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas

SCARINGI, CLAUDIA;DE SANCTIS, Vitaliana;FALCO, TERESA;ESPOSITO, Vincenzo;MAURIZI ENRICI, Riccardo;Giuseppe Minniti
2013

Abstract

To evaluate the efficacy of reirradiation and systemic chemotherapy as salvage treatment in patients with recurrent malignant glioma. Between May 2006 and December 2011, 54 patients with recurrent malignant glioma received hypofractionated stereotactic radiotherapy (HSRT) plus systemic therapy at University of Rome Sapienza, Sant' Andrea Hospital. All patients had Karnofsky performance score ≥60 and were previously treated with standard conformal RT (60 Gy) with concomitant and adjuvant temozolomide (TMZ) up to 12 cycles. Thirty-eight patients had a GBM and 16 patients had a grade 3 glioma. The median time interval between primary RT and reirradiation was 15.5 months. At the time of recurrence all patients received HSRT (30 Gy in 6-Gy fractions) plus concomitant TMZ (75 mg/m2/day) followed by continuous TMZ at 50 mg/m2 everyday up to 1 year or until progression. Median overall survival after HSRT was 12.4 months, and the 12- and 24-month survival rates were 53 and 16 %, respectively. The median progression-free survival (PFS) was 6 months, and the 12- and 24-month PFS rates were 24 and 10 %, respectively. KPS >70 (P = 0.04) and grade 3 glioma were independent favourable prognostic factors for survival. In general chemoradiation regimen was well tolerated with relatively low treatment-related toxicity. HSRT plus concomitant TMZ followed by continuous dose-intense TMZ is a feasible treatment option associated with survival benefits and low risk of complications in selected patients with recurrent malignant glioma. The potential advantages of combined chemoradiation schedules in patients with recurrent malignant gliomas need to be explored in future studies. © 2012 Springer Science+Business Media New York.
2013
methods; high grade glioma; brain neoplasms; aged; karnofsky performance status; glioma; temozolomide; follow-up studies; dihydroxyphenylalanine; retrospective studies; analogs /&/ derivatives/diagnostic use; disease-free survival; therapeutic use; reirradiation; dacarbazine; male; antineoplastic agents; middle aged; adult; humans; alkylating; radiosurgery; drug therapy/surgery; analogs /&/ derivatives/therapeutic use; recurrence; female; stereotactic radiotherapy; glioblastoma
01 Pubblicazione su rivista::01a Articolo in rivista
Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas / Giuseppe, Minniti; Scaringi, Claudia; DE SANCTIS, Vitaliana; Gaetano, Lanzetta; Falco, Teresa; D., Di Stefano; Esposito, Vincenzo; MAURIZI ENRICI, Riccardo. - In: JOURNAL OF NEURO-ONCOLOGY. - ISSN 0167-594X. - STAMPA. - 111:2(2013), pp. 187-194. [10.1007/s11060-012-0999-9]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/506194
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 50
  • ???jsp.display-item.citation.isi??? 47
social impact